Bright Minds Biosciences Inc.
NASDAQ:DRUGBiotechnology
+$0.62 today
- Market cap
- $204.78M
- Beta
- -0.11
- P/E (TTM)
- -29.8
- EPS (TTM)
- -$2.87
Volume 0.14M
Average 0.27M
DRUG Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Bright Minds Biosciences Inc.NASDAQ: DRUG
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of CA$13.27M rose 417.5% year over year, behind the +663.6% change in trailing-twelve-month research & development. Sequentially, it rose 134.3% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +417.5% toward the trailing-twelve-month pace of +663.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 11.08M CAD
- Year-over-year change
- +839.4%
- 4-year CAGR
- +15.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 11.08M | +839.4% |
| FY2024 | 2024-09-30 | 1.18M | -76.4% |
| FY2023 | 2023-09-30 | 5M | -59.0% |
| FY2022 | 2022-09-30 | 12.18M | +92.9% |
| FY2021 | 2021-09-30 | 6.31M | — |
Research & Development vs competitors
How DRUG compares with its peers on the latest reported figures
No competitor Research & Development figures are available to compare.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.31M | 12.18M | 5M | 1.18M | 11.08M |
| Selling, General & Admin | 2.31M | 2.55M | 2.2M | 1.45M | 2.57M |
| Operating Expenses | 8.62M | 14.98M | 7.39M | 2.82M | 13.94M |
| Depreciation & Amortization | 8.62M | 6.04K | 72.45K | 73.36K | 76.87K |
| EBITDA | (27.64K) | (14.96M) | (7.3M) | (2.73M) | (12.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.62M) | (14.98M) | (7.39M) | (2.82M) | (13.94M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 30.13K | 1.52M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (27.64K) | 10.15K | 14.19K | 20.82K | 1.71M |
| Income Before Tax | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.74) | (6.15) | (1.98) | (0.65) | (1.78) |
| EPS (Diluted) | (4.74) | (6.15) | (1.98) | (0.65) | (1.78) |
| Weighted Avg Shares | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M |
| Weighted Avg Shares (Diluted) | 1.79M | 2.47M | 3.72M | 4.31M | 6.88M |
Bright Minds Biosciences Inc.
NASDAQ:DRUG
Intrinsic Alpha fair value
Locked
Current Price
$20.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.